title: Helping patients make sense of the risks of taking GLP-1 agonists.
authors.forename: Victor M
authors.initials: VM
authors.lastname: Montori
mesh_terms: D058070:Asymptomatic Diseases / Q000628:therapy; D048909:Diabetes Complications / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D054795:Incretins / Q000819:agonists; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism; D017063:Outcome Assessment, Health Care; D018570:Risk Assessment
chemical_list: D007004:Hypoglycemic Agents; D054795:Incretins; D052216:Glucagon-Like Peptide 1